Having trouble accessing articles? Reset your cache.

Lymphoseek meets primary endpoint in SCCHN patients

Navidea Biopharmaceuticals Inc. (NYSE-M:NAVB) said preoperative imaging with a single injection of Lymphoseek tilmanocept met the primary endpoint in

Read the full 194 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE